Goldman Sachs Upgrades Taysha Gene Therapies on Rett Syndrome Potential
Goldman Sachs upgrades Taysha Gene Therapies to Buy with an $11 target, citing strong confidence in the company’s Rett syndrome program and REVEAL study expectations.
/ 433 items
#Healthcare↓
Stifel Bullish on Foghorn Therapeutics Stock
Stifel starts Foghorn Therapeutics coverage with Buy rating and $12 target. Lead drug FHD-909 partnership with Eli Lilly expected to launch in 2030 with strong sales potential.
Incannex IHL-42X Secures FDA Fast Track for OSA Treatment
Incannex's oral drug (IHL-42X) for serious sleep apnea (OSA) got FDA Fast Track status to speed up its development and potential approval.
Guggenheim Downgrades Black Diamond Therapeutics on Silevertinib Concerns
Guggenheim lowers Black Diamond Therapeutics to Neutral, citing toxicity and durability concerns in silevertinib’s Phase 2 trial and risks to key 2026 catalysts.
Protara Therapeutics Shares Climb on Strong Phase 2 Trial Results for TARA-002
Protara Therapeutics stock jumped after positive Phase 2 interim results showed strong response rates for TARA-002 in non-muscle invasive bladder cancer patients.
MapLight Therapeutics Gains from Bristol Myers’ ADEPT-2 Study Update
MapLight Therapeutics sees upside as Bristol Myers continues ADEPT-2 Alzheimer’s psychosis trial despite site irregularities, with potential catalysts for 2026.